Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study.
Cardiovascular disease
Cognitive decline
DPP-4 inhibitors
Sulfonylureas
Type 2 diabetes
Journal
Diabetologia
ISSN: 1432-0428
Titre abrégé: Diabetologia
Pays: Germany
ID NLM: 0006777
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
07
08
2020
accepted:
11
12
2020
pubmed:
10
2
2021
medline:
23
2
2022
entrez:
9
2
2021
Statut:
ppublish
Résumé
Type 2 diabetes, particularly with concomitant CVD, is associated with an increased risk of cognitive impairment. We assessed the effect on accelerated cognitive decline (ACD) of the DPP-4 inhibitor linagliptin vs the sulfonylurea glimepiride in individuals with type 2 diabetes. The CAROLINA-COGNITION study was part of the randomised, double-blind, active-controlled CAROLINA trial that evaluated the cardiovascular safety of linagliptin vs glimepiride in individuals with age ≥40 and ≤85 years and HbA Of 6033 participants recruited from hospital and primary care sites, 3163 (38.0% female, mean age/diabetes duration 64/7.6 years, MMSE score 28.5, HbA In a large, international outcome trial in people with relatively early type 2 diabetes at elevated cardiovascular risk, no difference in risk for ACD was observed between linagliptin and glimepiride over 6.1 years. This study was sponsored by Boehringer Ingelheim. ClinicalTrials.gov NCT01243424.
Identifiants
pubmed: 33559704
doi: 10.1007/s00125-021-05393-8
pii: 10.1007/s00125-021-05393-8
pmc: PMC8099814
doi:
Substances chimiques
Blood Glucose
0
Hypoglycemic Agents
0
Sulfonylurea Compounds
0
Linagliptin
3X29ZEJ4R2
glimepiride
6KY687524K
Banques de données
ClinicalTrials.gov
['NCT01243424']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1235-1245Subventions
Organisme : NIA NIH HHS
ID : P30 AG049638
Pays : United States
Références
Biessels GJ, Despa F (2018) Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications. Nat Rev Endocrinol 14:591–604. https://doi.org/10.1038/s41574-018-0048-7
doi: 10.1038/s41574-018-0048-7
pubmed: 30022099
pmcid: 6397437
Stefanidis KB, Askew CD, Greaves K, Summers MJ (2018) The effect of non-stroke cardiovascular disease states on risk for cognitive decline and dementia: a systematic and meta-analytic review. Neuropsychol Rev 28:1–15. https://doi.org/10.1007/s11065-017-9359-z
doi: 10.1007/s11065-017-9359-z
pubmed: 28856507
Biessels GJ, Strachan MW, Visseren FL, Kappelle LJ, Whitmer RA (2014) Dementia and cognitive decline in type 2 diabetes and prediabetic stages: towards targeted interventions. Lancet Diabetes Endocrinol 2:246–255. https://doi.org/10.1016/S2213-8587(13)70088-3
doi: 10.1016/S2213-8587(13)70088-3
pubmed: 24622755
Haroon NN, Austin PC, Shah BR, Wu J, Gill SS, Booth GL (2015) Risk of dementia in seniors with newly diagnosed diabetes: a population-based study. Diabetes Care 38:1868–1875. https://doi.org/10.2337/dc15-0491
doi: 10.2337/dc15-0491
pubmed: 26216873
Moore EM, Mander AG, Ames D et al (2013) Increased risk of cognitive impairment in patients with diabetes is associated with metformin. Diabetes Care 36(10):2981–2987. https://doi.org/10.2337/dc13-0229
doi: 10.2337/dc13-0229
pubmed: 24009301
pmcid: 3781568
Exalto LG, Biessels GJ, Karter AJ et al (2013) Risk score for prediction of 10 year dementia risk in individuals with type 2 diabetes: a cohort study. Lancet Diabetes Endocrinol 1:183–190. https://doi.org/10.1016/S2213-8587(13)70048-2
doi: 10.1016/S2213-8587(13)70048-2
pubmed: 24622366
pmcid: 4429783
International Diabetes Federation (2019) IDF diabetes atlas, 9th edn. International Diabetes Federation, Brussels. Available from: https://www.diabetesatlas.org/en/resources/ . Accessed Oct 13 2020
de Galan BE, Zoungas S, Chalmers J et al (2009) Cognitive function and risks of cardiovascular disease and hypoglycemia in patients with type 2 diabetes: the action in diabetes and vascular disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Diabetologia 52:2328–2336. https://doi.org/10.1007/s00125-009-1484-7
doi: 10.1007/s00125-009-1484-7
pubmed: 19688336
Groeneveld ON, van den Berg E, Johansen OE et al (2019) Oxidative stress and endothelial dysfunction are associated with reduced cognition in type 2 diabetes. Diab Vasc Dis Res 16:577–581. https://doi.org/10.1177/1479164119848093
doi: 10.1177/1479164119848093
pubmed: 31068001
Verma N, Despa F (2019) Contributing factors to diabetic brain injury and cognitive decline. Diabetes Metab J 43:560–567. https://doi.org/10.4093/dmj.2019.0153
doi: 10.4093/dmj.2019.0153
pubmed: 31694078
pmcid: 6834839
Crane PK, Walker R, Hubbard RA et al (2013) Glucose levels and risk of dementia. N Engl J Med 369:540–548. https://doi.org/10.1056/NEJMoa1215740
doi: 10.1056/NEJMoa1215740
pubmed: 23924004
pmcid: 3955123
Janssen J, van den Berg E, Zinman B et al (2019) HbA
doi: 10.2337/dc18-0914
Areosa Sastre A, Vernooij RW, González-Colaço Harmand M, Martínez G (2017) Effect of the treatment of type 2 diabetes mellitus on the development of cognitive impairment and dementia. Cochrane Database Syst Rev 6:CD003804. https://doi.org/10.1002/14651858.CD003804.pub2
doi: 10.1002/14651858.CD003804.pub2
pubmed: 28617932
Imfeld P, Bodmer M, Jick SS, Meier CR (2012) Metformin, other antidiabetic drugs, and risk of Alzheimer’s disease: a population based case-control study. J Am Geriatr Soc 60:916–921. https://doi.org/10.1111/j.1532-5415.2012.03916.x
doi: 10.1111/j.1532-5415.2012.03916.x
pubmed: 22458300
Luschinger JA, Ma Y, Christophi CA et al (2017) Metformin, lifestyle intervention, and cognition in the diabetes prevention program outcomes study. Diabetes Care 40:958–965. https://doi.org/10.2337/dc16-2376
doi: 10.2337/dc16-2376
Weinstein G, Davis-Plourde KL, Conner S et al (2019) Association of metformin, sulfonylurea and insulin use with brain structure and function and risk of dementia and Alzheimer’s disease: pooled analysis from 5 cohorts. PLoS One 14:e0212293. https://doi.org/10.1371/journal.pone.0212293
doi: 10.1371/journal.pone.0212293
pubmed: 30768625
pmcid: 6377188
Cukierman-Yaffe T, Bosch J, Diaz R et al (2014) Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial. Lancet Diabetes Endocrinol 2:562–572. https://doi.org/10.1016/S2213-8587(14)70062-2
doi: 10.1016/S2213-8587(14)70062-2
pubmed: 24898834
Athauda D, Maclagan K, Skene SS et al (2017) Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet 390:1664–1675. https://doi.org/10.1016/S0140-6736(17)31585-4
Shannon RP (2013) DPP-4 inhibition and neuroprotection: do mechanisms matter? Diabetes 62:1029–1031. https://doi.org/10.2337/db12-1794
Cukierman-Yaffe T, Gerstein HC, Colhoun HM et al (2020) Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. Lancet Neurol 19:582–590. https://doi.org/10.1016/S1474-4422(20)30173-3
doi: 10.1016/S1474-4422(20)30173-3
pubmed: 32562683
Lin Z, Huang H, Gu Y et al (2017) Glibenclamide ameliorates cerebral edema and improves outcomes in a rat model of status epilepticus. Neuropharmacology 121:1–11. https://doi.org/10.1016/j.neuropharm.2017.04.016
Hussien NR, Al-Naimi MS, Rasheed HA, Al-Kuraishy HM, Al-Gareeb AI (2018) Sulfonylurea and neuroprotection: the bright side of the moon. J Adv Pharm Technol Res 9:120–123. https://doi.org/10.4103/japtr.JAPTR_317_18
doi: 10.4103/japtr.JAPTR_317_18
pubmed: 30637228
pmcid: 6302683
Lee AK, Rawlings AM, Lee CJ et al (2018) Severe hypoglycemia, mild cognitive impairment, dementia and brain volumes in older adults with type 2 diabetes: the Atherosclerosis Risk in Communities (ARIC) cohort study. Diabetologia 61:1956–1965. https://doi.org/10.1007/s00125-018-4668-1
doi: 10.1007/s00125-018-4668-1
pubmed: 29961106
pmcid: 6152822
Cukierman-Yaffe T, Bosch J, Jung H, Punthakee Z, Gerstein HC (2019) Hypoglycemia and incident cognitive dysfunction: a post-hoc analysis from the ORIGIN trial. Diabetes Care 42:142–147
doi: 10.2337/dc18-0690
Fink HA, Jutkowitz E, McCarten JR et al (2018) Pharmacologic interventions to prevent cognitive decline, mild cognitive impairment, and clinical Alzheimer-type dementia: a systematic review. Ann Intern Med 168:39–51. https://doi.org/10.7326/M17-1529
doi: 10.7326/M17-1529
pubmed: 29255847
Biessels GJ, Verhagen C, Janssen J et al (2019) Effect of linagliptin on cognitive performance in patients with type 2 diabetes and Cardiorenal comorbidities: the CARMELINA randomized trial. Diabetes Care 42:1930–1938. https://doi.org/10.2337/dc19-0783
doi: 10.2337/dc19-0783
pubmed: 31399442
Rosenstock J, Kahn SE, Johansen OE et al (2019) Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA 322:1155–1166. https://doi.org/10.1001/jama.2019.13772
Biessels GJ, Janssen J, van den Berg E et al (2018) Rationale and design of the CAROLINA® - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus. BMC Neurol 18:7
doi: 10.1186/s12883-018-1014-7
Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198. https://doi.org/10.1016/0022-3956(75)90026-6
doi: 10.1016/0022-3956(75)90026-6
pubmed: 1202204
pmcid: 1202204
Tombaugh TN, McIntyre N (1992) The mini-mental state examination: a comprehensive review. J Am Geriatr Soc 40:922–935
doi: 10.1111/j.1532-5415.1992.tb01992.x
Corrigan JD, Hinkeldey NS (1987) Relationships between parts A and B of the trail making test. J Clin Psychol 43:402–409. https://doi.org/10.1002/1097-4679(198707)43:4<402::AID-JCLP2270430411>3.0.CO;2-E
doi: 10.1002/1097-4679(198707)43:4<402::AID-JCLP2270430411>3.0.CO;2-E
pubmed: 3611374
Shao Z, Janse E, Visser K, Meyer AS (2014) What do verbal fluency tasks measure? Predictors of verbal fluency performance in older adults. Front Psychol 5:772. https://doi.org/10.3389/fpsyg.2014.00772
doi: 10.3389/fpsyg.2014.00772
pubmed: 4106453
pmcid: 4106453
Radloff LS (1977) The CES-D scale. A self-report depression scale for research in the general population. Appl Psychol Meas 1:385–401
doi: 10.1177/014662167700100306
Jonker C, Geerlings MI, Schmand B (2000) Are memory complaints predictive for dementia? A review of clinical and population-based studies. Int J Geriatr Psychiatry 15:983–991. https://doi.org/10.1002/1099-1166(200011)15:11<983::AID-GPS238>3.0.CO;2-5
doi: 10.1002/1099-1166(200011)15:11<983::AID-GPS238>3.0.CO;2-5
pubmed: 11113976
Espeland MA, Rapp SR, Bray GA et al (2014) Long-term impact of behavioral weight loss intervention on cognitive function: the Action for Health in Diabetes Movement and Memory study. J Gerontol A Biol Sci Med Sci 69:1101–1108. https://doi.org/10.1093/gerona/glu031
doi: 10.1093/gerona/glu031
pubmed: 24619151
pmcid: 4158413
Kikuchi Y, Iwase M, Fujii H et al (2015) Association of severe hypoglycemia with depressive symptoms in patients with type 2 diabetes: the Fukuoka Diabetes Registry. BMJ Open Diabetes Res Care 3:e000063. https://doi.org/10.1136/bmjdrc-2014-000063
doi: 10.1136/bmjdrc-2014-000063
pubmed: 26019877
pmcid: 4442133